Be careful seeing AEZS as worthwhile, 99% of shareholders would disagree and for good reason. Don't be surprised if your looking at the new highs. This company should be on the OTC based on how mgmt has treated shareholders over the years. Only success they've had in 5 years is their dilution efforts, all drugs have failed despite mgmt's assurances of success, hence the ongoing lawsuits and almost certain RS coming. Good luck.
News 
Market Data 
Discover 
AI
